MedTrace Logo

Prospective REgistry of Targeted RadionucLide TherapY in Patients With mCRPC (REALITY Study)

NCT04833517 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2022-12-08

No results posted yet for this study

Summary

This prospective registry aims to assess outcome and toxicity of targeted radionuclide therapies in patients with advanced prostate cancer in clinical routine. While the major investigated treatment modality is prostate-specific membrane antigen (PSMA)-targeted radioligand therapy, also other radionuclide therapies such as Ra223 and liver-directed radioembolization are included. The investigators believe that prospectively assessed long-term outcome data on implementation of radionuclide therapy, especially in the palliative setting of advanced mCRPC, help to better define the real benefits and risks of the respective treatment modalities for patients regarding survival and quality-of-life.

Conditions

  • Prostate Cancer Metastatic
  • Castration Resistant Prostatic Cancer
  • Advanced Prostate Carcinoma

Sponsors & Collaborators

  • Universität des Saarlandes

    lead OTHER

Principal Investigators

  • Samer Ezziddin, MSc, MD, PhD · Universität des Saarlandes

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-01
Primary Completion
2024-12-31
Completion
2025-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04833517 on ClinicalTrials.gov